Department of Otolaryngology Head and Neck Surgery, The First People's Hospital of Foshan, Guangdong, China.
Department of Nosocomial Infection Control, The First People's Hospital of Foshan, Guangdong, China.
Aging (Albany NY). 2020 Nov 26;13(1):769-781. doi: 10.18632/aging.202183.
Head and neck squamous cell carcinoma (HNSCC), which occurs frequently worldwide, is characterized by high risk of metastasis. MicroRNAs (miRNAs) play crucial roles in tumorigenesis and cancer development. In this study, miR-29c-5p was identified using three high throughput microarrays. We measure miR-29c-5p expression in HNSCC tissues and cell lines. To determine the function of miR-29c-5p in HNSCC, we evaluated its effects in vitro on cell proliferation, the cell cycle, apoptosis, and cell migration. We employed a mouse tumor xenograft model to determine the effects of miR-29c-5p on tumors generated by HNSCC cell lines. The miR-29c-5p expression was lower in HNSCC tissues than in normal tissues. Upregulated miR-29c-5p expression in HNSCC cells inhibited migration and arrested cells in the G2/M phase of the cell cycle. Further, upregulated miR-29c-5p expression inhibited the proliferation of HNSCC cells and . In addition, transmembrane protein 98 (TMEM98) was identified as a direct target of miR-29c-5p by using a luciferase reporter assay. These findings provide new insights that link the regulation of miR-29c-5p expression to the malignant phenotype of HNSCC and suggest that employing miR-29c-5p may serve as a therapeutic strategy for managing patients with HNSCC.
头颈部鳞状细胞癌(HNSCC)在全球范围内发病率较高,其特征为转移风险高。微小 RNA(miRNA)在肿瘤发生和癌症发展中起着至关重要的作用。在这项研究中,使用三个高通量微阵列鉴定了 miR-29c-5p。我们测量了 HNSCC 组织和细胞系中的 miR-29c-5p 表达。为了确定 miR-29c-5p 在 HNSCC 中的功能,我们在体外评估了其对细胞增殖、细胞周期、细胞凋亡和细胞迁移的影响。我们采用小鼠肿瘤异种移植模型来确定 miR-29c-5p 对 HNSCC 细胞系生成的肿瘤的影响。与正常组织相比,HNSCC 组织中的 miR-29c-5p 表达较低。HNSCC 细胞中 miR-29c-5p 的上调表达抑制了迁移,并使细胞周期停滞在 G2/M 期。此外,上调 miR-29c-5p 表达抑制了 HNSCC 细胞的增殖。另外,通过荧光素酶报告基因检测鉴定跨膜蛋白 98(TMEM98)为 miR-29c-5p 的直接靶标。这些发现提供了新的见解,将 miR-29c-5p 表达的调控与 HNSCC 的恶性表型联系起来,并表明使用 miR-29c-5p 可能成为管理 HNSCC 患者的治疗策略。